Indivior PLC reported its third‑quarter 2025 results, posting net revenue of $314 million, a 2 % year‑over‑year increase, and adjusted EBITDA of $120 million. Net income rose to $42 million, translating to GAAP diluted earnings per share of $0.33. The company highlighted that SUBLOCADE generated $219 million of the quarter’s revenue, up 15 % year‑over‑year, and that the U.S. segment contributed $267 million, reflecting continued demand for its long‑acting injectable.
Indivior raised its full‑year 2025 guidance. Net revenue is now expected to be between $1,180 million and $1,220 million, up from the prior $1,030 million to $1,080 million range. Adjusted EBITDA guidance has been lifted to $400 million to $420 million, with the higher range of $275 million to $300 million now the previous target. Guidance for SUBLOCADE net revenue was not explicitly updated in the release.
CEO Joe Ciaffoni noted that the company has completed Phase I of its Action Agenda, achieving stronger SUBLOCADE performance and simplifying operations. He said the company is on track to realize at least $150 million in annual operating‑expense savings beginning in 2026, and that the simplified operating model will generate immediate accretion to the bottom line and improved cash generation from January 2026 onward.
The earnings release confirmed that the company’s cost‑reduction initiatives, including headcount reductions and the discontinuation of commercial support for OPVEE, are delivering the expected financial benefits. The guidance lift reflects confidence in sustained SUBLOCADE demand, stable SUBOXONE film pricing, and the anticipated impact of the company’s ongoing operational simplification.
Prior‑period comparisons show that Q3 2024 net income was $22 million and diluted EPS was a loss of $0.16, while Q2 2025 net income was $22 million. The company’s ROW net revenue increased 2 % at actual exchange rates to $47 million. The company faces headwinds from generic competition eroding SUBOXONE film sales, but it continues to invest in marketing and anticipates FDA label updates to strengthen its competitive position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.